终末期酒精性肝病患者酒精使用障碍的诊断与治疗
全球14%-30%人群受酒精使用障碍(AUD)影响,过量饮酒是西方世界最常见肝病病因。终末期酒精性肝病临床表现复杂,戒酒是管理核心,心理社会干预常不足,药物治疗选择因肝性脑病等禁忌受限,需多学科综合管理。
要点
- 全球14%-30%人群受酒精使用障碍影响,过量饮酒是西方最常见肝病病因。
- 达到并维持戒酒是AUD合并终末期肝病管理的主要支柱。
- 终末期肝病中药物治疗选择有限,多学科综合管理极具挑战。
核心结论
- 达到并维持戒酒是管理AUD合并终末期肝病患者的主要支柱,心理社会干预是治疗的重要组成部分,但常不足,需联合药物治疗和多学科综合管理。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 全球14%-30%人群受酒精使用障碍影响,过量饮酒是西方世界最常见肝病病因。
- 终末期酒精性肝病临床表现复杂,戒断综合征、渴求、躯体依赖及肝外酒精相关疾病与晚期肝硬化并发症交织。
- 许多治疗戒断综合征的常用药物常因肝性脑病或肝肾综合征而禁忌。
- 心理社会干预常因功能与身体状况差致依从性不足而效果有限。
- 许多GABA能药物可促进肝性脑病发生,经广泛肝代谢的药物应避免或极谨慎使用。
临床怎么用
- 作者认为,达到并维持戒酒是管理AUD合并终末期肝病患者的主要支柱。
- 作者认为,心理社会干预是治疗的重要组成部分,但常不足,需联合药物治疗。
- 作者认为,终末期AUD管理极具挑战,需要多学科综合方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Between 14%-30% of the world's population is affected by alcohol use disorder (AUD), and excessive alcohol consumption represents the most common cause of liver disease in the western world. The clinical picture of alcoholic end-stage liver disease is rendered extremely complex, as manifestations such as alcohol withdrawal syndrome, craving and physical dependence, as well as extrahepatic alcohol-related diseases merge with the complications of advanced cirrhosis. This makes AUD recognition and assessment difficult and its management arduous as many drugs commonly used to treat complications such as alcohol withdrawal syndrome are often contraindicated by the presence of hepatic encephalopathy or hepatorenal syndrome. Reaching and maintaining abstinence represents the mainstay of managing patients with AUD and end-stage liver disease. Psychosocial interventions are an essential component of treatment to reach these goals. However, these interventions alone often prove insufficient in AUD patients and even more frequently in those with end-stage liver disease because of inadequate adherence due to poor functional and physical status. Pharmacological treatments need to be associated, but the available options are greatly limited in end-stage liver disease because many GABA-Ergic drugs can favor the development of hepatic encephalopathy, whereas drugs undergoing extensive liver metabolism should be avoided or used with the greatest caution. Because of these limitations, the management of end-stage AUD is extremely challenging and requires an integrated multidisciplinary approach.
引用
- Caputo F, Domenicali M, Bernardi M, et al. Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease. Hepatology. 2019. PMID: 30471136. doi:10.1002/hep.30358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。